

Microbisporicin (NAI-107) protects *Galleria mellonella* from infection with *Neisseria gonorrhoeae*

Nele Hofkens,¹ Zina Gestels,¹ Said Abdellati,² Irith De Baetselier,² Philippe Gabant,³ Anandi Martin,³ Christopher Kenyon,^{1,4} Sheeba Santhini Manoharan-Basil¹

AUTHOR AFFILIATIONS See affiliation list on p. 10.

ABSTRACT Due to the increasing incidence of antibiotic-resistant bacterial pathogens, the need for the development of alternative compounds is of utmost importance. Bacteriocins are considered a promising alternative to antibiotics. In this study, we determined the *in vitro* activities of 65 bacteriocins from the PARAGEN collection along with microbisporicin (NAI-107) against 14 WHO reference isolates of *Neisseria gonorrhoeae*, one isolate of *Neisseria meningitidis*, and four commensal *Neisseria* spp. The initial screening of the bacteriocins was carried out using a spot-on-lawn assay wherein 12 bacteriocins (12/66) showed a zone of inhibition against the WHO-P *N. gonorrhoeae* isolate. Four bacteriocins (4/12), Garvicin KS (GarKS) (ABC), lacticin (Lcn) Q, Lcn Z, and NAI-107, demonstrated higher activity, and minimum inhibitory concentrations (MICs) using agar dilutions were determined for 19 *Neisseria* spp. GarKS (ABC), Lcn Q, and Lcn Z had an MIC range of 4–16 µg/mL, whereas NAI-107 had an MIC range of <0.25 to 2 µg/mL. Using an *in vivo* *Galleria mellonella* model, we determined the efficacy of GarKS (ABC), Lcn Z, and NAI-107. GarKS (ABC) and Lcn Z displayed no *in vivo* toxicity but showed no *in vivo* activity against WHO-P *N. gonorrhoeae*. In contrast, NAI-107 was as effective as ceftriaxone and significantly increased the survival rate of WHO-P *N. gonorrhoeae*-infected *G. mellonella* larvae. In conclusion, NAI-107 exhibited potent *in vitro* and *in vivo* activities against *N. gonorrhoeae*. To our knowledge, this is the first study to demonstrate that NAI-107 possesses anti-gonococcal activity *in vivo*.

IMPORTANCE We screened 66 bacteriocins to see if they exhibited anti-gonococcal activity. We found 12 bacteriocins with anti-gonococcal effects, and 4 bacteriocins showed higher anti-gonococcal activity. Three bacteriocins, lacticin Z, lacticin Q, and Garvicin KS (ABC), showed *in vitro* anti-gonococcal activity but no *in vivo* inhibitory effects against the *Neisseria gonorrhoeae* (WHO-P) isolate. On the other hand, NAI-107 showed *in vivo* anti-gonococcal activity. The findings suggest that NAI-107 is a promising alternative to treat gonorrhea infections.

KEYWORDS *Neisseria gonorrhoeae*, lantibiotics, NAI-107, microbisporicin, *Galleria mellonella*

The emergence, spread, and persistence of multidrug-resistant (MDR) bacteria pose a global threat of growing concern to human, animal, and environmental health. The scarcity of new antibacterial drugs in the development pipeline exacerbates the serious threat to public health posed by the spread of antibiotic resistance, which is forecast to reach dramatic levels by 2050 (1–4). The majority of antibiotics used in clinical practice today are microbial metabolites or their derivatives, and alternative approaches to antibiotic discovery have not been as successful as microbial product screening (5, 6). The increasing incidence of antibiotic-resistant bacterial pathogens highlights the urgent need for new antimicrobial agents, especially those with new modes of action (2).

Editor John M. Attack, Griffith University - Gold Coast Campus, Southport, Gold Coast, Queensland, Australia

Address correspondence to Sheeba Santhini Manoharan-Basil, sbasil@itg.be.

Christopher Kenyon and Sheeba Santhini Manoharan-Basil contributed equally to this article.

The authors declare no conflict of interest.

Received 11 July 2023

Accepted 6 September 2023

Published 12 October 2023

Copyright © 2023 Hofkens et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Gonorrhea caused by the pathogen *Neisseria gonorrhoeae* is the second most common bacterial sexually transmitted infection (STI). In 2020, the World Health Organization (WHO) estimated that 82.4 million new gonorrhea cases occurred in adults globally (7). Complications of gonorrhea include pelvic inflammatory disease, infertility, and ectopic pregnancy in women, epididymal orchitis in men, neonatal ophthalmia, and an elevated risk for HIV acquisition and transmission (8–11). The increased emergence of antimicrobial resistance (AMR) in *N. gonorrhoeae* has heightened the need for new first-line antimicrobials for the treatment of gonorrhea (11).

Bacteriocins are antimicrobial peptides produced by bacteria with either a broad or narrow spectrum of antibacterial activity (12–14). According to the Cotter et al. scheme, bacteriocins are classified into lanthionine (class I) and non-lanthionine-containing (class II) bacteriocins (15). Lantibiotics (class I) are ribosomally synthesized, post-translationally modified peptides (RiPPs) (16). They are small (<5 kDa) peptides and are synthesized as a precursor peptide, lanthionine (LanA), with an N-terminal leader peptide (NP) and a C-terminal core peptide (CP) (17). They undergo post-translational modifications (PTMs) with the formation of 3-methylanthionine (MeLan), dehydroalanine (Dha), and/or dehydrobutyrine (Dhb) residues that occur *via* the dehydration of serine and threonine residues, respectively, which are then crosslinked *via* a thioether linkage with cysteine residues and a number of dehydrated amino acids that gives lantibiotics their characteristic conformation and stability (15–22). Examples include microbisporicin (NAL-107) produced by the actinomycete *Microbispora corallina* ATCC-PTA-5024 (23–28) and nisin Z from *Lactococcus lactis* IO-1 (29). Class II bacteriocins are the most frequent naturally occurring bacteriocins. They are small (<10 kDa), are heat-stable, and, unlike lantibiotics, do not undergo extensive post-translational modification. Examples include lacticin Z (lcn Z) and lacticin Q (lcn Q) produced by *L. lactis* QU 14 and QU 5, respectively (30, 31), and Garvicin KS (GakKS) produced by *Lactococcus garvieae* KS1546 (32).

Bacteriocins have gained considerable attention as potential alternatives to traditional antibiotics due to their narrow-spectrum activity and a lower likelihood of inducing resistance (12–14, 33). Most leaderless bacteriocins, such as lacticin Q (53 aa), lacticin Z (53 aa), and Garvicin KS [composed of three peptides (GakA, GakB, and GakC, 30–34 aa)], have been shown to have inhibitory effects against a range of genera, such as *Bacillus*, *Listeria*, *Staphylococcus*, and *Enterococcus* (32, 34). NAL-107 has been found to be active against a wide range of MDR Gram-positive bacterial pathogens, including methicillin-resistant *Staphylococcus aureus* (MRSA), glycopeptide-intermediate-resistant *S. aureus* (GISA), vancomycin-resistant enterococci (VRE), penicillin-resistant *Streptococcus pneumoniae*, and a selected range of Gram-negative bacteria—*N. gonorrhoeae* and *Moraxella* spp. (24, 33, 35).

Galleria mellonella larvae have been previously used as a model host for studying various pathogens and the efficacy of various antimicrobial agents (36–43). This system provides an alternative *in vivo* model to mammalian systems, and its immune system involves both cellular (phagocytosis, nodulization, and encapsulation) and humoral defenses (melanization, hemolymph clotting, and production of antimicrobial peptides) and shares a high degree of structural and functional similarity with that of mammals (36).

The *in vitro* antimicrobial activity of bacteriocins against relevant pathogenic bacteria (including MDR pathogens) has been well documented (44–47). However, the use of *in vivo* studies is an important step forward for the development of new therapeutic agents (48). The present study investigated the *in vitro* antibacterial activity of lantibiotics ($n = 66$) and the *in vivo* antibacterial activity of three bacteriocins against WHO-P *Neisseria gonorrhoeae* using the wax moth larva *G. mellonella*. The results highlight the potential of bacteriocins as alternative therapeutic agents for treating *N. gonorrhoeae* infections.

MATERIALS AND METHODS

Bacterial isolates

The following isolates were used in the present study: *N. gonorrhoeae* WHO reference isolates ($n = 14$), *N. meningitidis* ($n = 1$, ITM 3354), *Neisseria mucosa* ($n = 1$, ATCC 25999), *Neisseria subflava* (ITM 3367), *Neisseria cinerea* (ATCC 14685), *Neisseria lactamica* ($n = 1$, ATCC 23970), and *L. lactis* subsp. *lactis* IL1403 ($n = 1$) (Table 2). In Belgium, resistance to gonococcal azithromycin has increased from 0.2% to 18.6% over the past 8 years, despite the use of dual therapy, i.e., ceftriaxone and azithromycin (49). Therefore, in this study, the WHO-P *N. gonorrhoeae* isolate was used in the initial *in vitro* screening and *in vivo* experiments due to its susceptibility to ceftriaxone (0.004 $\mu\text{g}/\text{mL}$) and resistance to azithromycin (4 $\mu\text{g}/\text{mL}$), as determined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria (50).

In vitro studies

Source of bacteriocins and determination of the anti-gonococcal activity of bacteriocins

Sixty-five bacteriocins from the PARAGEN synthetic DNA library collection from the Belgian start-up Syngulon (51) and NAI-107 (AdipoGen Life Sciences) were used in the study. The stock of each bacteriocin from PARAGEN was prepared in molecular biology-grade water (AccuGENE). NAI-107 was dissolved in 15% dimethyl sulfoxide (DMSO). The bacteriocins were stored at -20°C until further use. The antibacterial activities of the bacteriocins against the azithromycin-resistant WHO-P *N. gonorrhoeae* isolate were tested by spot-on-lawn assay. Briefly, the direct colony suspension method was used to grow the WHO-P isolate, wherein the inoculum was prepared using phosphate-buffered saline (PBS) from isolated colonies grown overnight on a gonococcal (GC) [containing 15 g/L Bacto protease peptone, 1 g/L soluble starch, 4 g/L K_2HPO_4 (174.18 g/mol), 1 g/L KH_2PO_4 (136.08 g/mol), and 5 g/L NaCl (58.44 g/mol), supplemented with 1% BD BBL IsoVitalEx] agar plate. The turbidity of the suspension was adjusted to a 0.5 McFarland standard. Specifically, 100 μL of the inoculum suspension was added to 5 mL of GC soft agar, mixed, and overlaid on the surface of the GC agar plate and allowed to solidify. Two microliters of the bacteriocin was spotted on the surface. Plates were incubated in a 5% CO_2 incubator at 37°C for 24 hours. The antimicrobial activity was evaluated based on the zone of inhibition (ZOI). Based on the size of the ZOI, a select number of antimicrobial bacteriocins were used to determine the minimum inhibitory concentration (MIC).

Minimum inhibitory concentrations of lacticin Z, lacticin Q, GarkS ABC, and NAI-107 against *Neisseria* species

The MICs were determined using the agar dilution method based on the Clinical and Laboratory Standards Institute (CLSI) for the four bacteriocins (lacticin Z, lacticin Q, GarkS ABC, and NAI-107) against 19 *Neisseria* spp. (52). *L. lactis* IL1403, for which the PARAGEN collection bacteriocins showed antibacterial activity by spot assays, was used as a positive control (53).

In brief, for the agar dilution, a series of GC agar plates with 1% IsoVitalEx containing the bacteriocin to be tested in increasing concentrations in doubling dilutions (i.e., 2, 4, 8, and 16 $\mu\text{g mL}^{-1}$ for lacticin Z, lacticin Q, and GarkS ABC and 0.25, 0.5, 1, 2, and 4 $\mu\text{g mL}^{-1}$ for NAI-107) were prepared. The strains were suspended in Mueller-Hinton (MH) broth to equal the turbidity of a 0.5 McFarland standard [$\sim 1 \times 10^8$ colony forming units (CFU) mL^{-1}], and 200 μL of one-tenth dilution of the suspension was placed on the inoculum plate. The inoculum was transferred using an AQS A400 Multipoint Inoculator (the final inoculum is $\sim 10^3$ CFU/spot). Blood agar and GC agar plates with no bacteriocin added served as the growth control plates. The agar plates were incubated at 37°C for 18–24 hours in 5% CO_2 . After incubation, the MIC was considered the lowest concentration of the tested material that inhibited the visible growth of the bacteria.

Serial passage experiments and evaluation of the potential for in vitro resistance development to NAI-107

N. gonorrhoeae WHO-P was propagated by serial passages with increasing concentrations of NAI-107 (0.25, 0.5, 1, 2, and 4 µg/mL) in quadruplicate. The selection of WHO-P was performed on GC agar plates supplemented with various concentration gradients of NAI-107 with an initial low sub-MIC concentration (one-fourth of MIC) of 0.25 µg/mL and incubated at 37°C in 5% CO₂. After visible growth was attained, colonies were subcultured onto GC agar plates with twofold serial bacteriocin concentrations. The serial passage was repeated until no visible growth was seen on the GC agar plate.

In vivo studies

Co-culturing of *N. gonorrhoeae* with the hemolymph from *G. mellonella*

The *N. gonorrhoeae* inoculum for infection in *G. mellonella* was prepared as follows: the WHO-P *N. gonorrhoeae* isolate was cultured from frozen stocks onto BD Columbian Blood Agar with 5% sheep blood for 24 hours at 37°C with 5% (v/v) CO₂. Single colonies were plated onto fresh BD chocolate blood agar plates and incubated. A loopful of the culture from the agar plates was suspended in PBS containing the hemolymph from *G. mellonella* larvae. The mixture was incubated at 37°C with 5% (v/v) CO₂ for an hour and plated on fresh BD BBL GC-lect selective agar to enrich the growth and recovery of *N. gonorrhoeae* specifically. This inoculum was used to infect *G. mellonella* subsequently.

Determining the maximum nonlethal dose of *N. gonorrhoeae*


G. mellonella larvae were treated with a range of inoculating doses of *N. gonorrhoeae* WHO-P (1.5×10^8 – 1.2×10^9 CFU/mL) and observed for death alongside PBS controls. The maximum nonlethal dose was determined and used as the inoculating dose for infection. The nonlethal dose with 80% mortality was observed at concentrations as high as 9.0×10^8 CFU/mL and was used in the *G. mellonella* model.

***Galleria mellonella* infection model**


Injection of *G. mellonella* was carried out as described in reference (43). The last larval stage of *G. mellonella* (Terramania, Arnhem, Netherlands) was used for the experiments. Only macroscopically healthy, non-discolored larvae were selected. The larvae were inoculated in the last left proleg using 0.3-mL U-100 insulin syringes (BD Micro-Fine). Two test groups were evaluated: (i) to assess the efficacy, test group 1 consisted of 20 larvae per concentration of each bacteriocin or ceftriaxone (20 mg/kg). About 30 µL of the 3.0-McFarland (2.7×10^7 CFU/mL) *N. gonorrhoeae* inoculum in PBS was used to infect *G. mellonella* larvae. The larvae were treated with 1× MIC, 2× MIC, 4× MIC, and 8× MIC of GarKS (ABC) and lacticin Z and 4× MIC, 8× MIC, and 16× MIC of NAI-107; (ii) to assess the toxicity, test group 2 with five larvae per concentration of bacteriocin was used. The efficacy test group 1 first received the *N. gonorrhoeae* inoculum, followed by the bacteriocin or antimicrobial, whereas the toxicity test group 2 received only the bacteriocin. One positive and two negative control groups were used. The positive control group received only the *N. gonorrhoeae* inoculum in PBS. Out of the two negative control groups, one group underwent no manipulation, while the other group was injected with PBS only. Each group was incubated in sterile Petri dishes at 37°C with a 5% (v/v) CO₂ atmosphere for the duration of the experiments. The larvae were observed for 120 hours for any indications of illness, necrosis, or paralysis, which enabled an evaluation of the bacteriocin's toxicity. Larvae were scored dead if they did not respond to touch stimuli by blunt sterile forceps and scored for five consecutive days (120 hours).

An overview of the study is provided in Fig. 1.


1) Initial screening of PARAGEN collection using spot on lawn assay



2) MIC determination using agar dilution



3) Serial passage experiment



4) *Galleria mellonella* infection model




FIG 1 Overview of the study. The figure was created using BioRender.

Statistical analysis

Data were analyzed using GraphPad Prism v9. Survival plots were created using Kaplan-Meier survival curves. Statistical analysis was carried out using the Mantel-Cox test to compare survival curves between the PBS controls and each treatment arm. A *P* value of <0.05 was considered statistically significant.

Pearson's correlation coefficient was determined for NAI-107 vs ceftriaxone and NAI-107 vs azithromycin. A Pearson's correlation coefficient (*r*) of 1 indicated a perfect direct relationship, an *r* value of -1 indicated a perfect inverse relationship, and an *r* value of 0 indicated no relationship between the two variables. Statistical analysis was performed using RStudio (2022.07.1).

RESULTS

In vitro anti-gonococcal activity of bacteriocins and MICs

Using the spot-on-lawn assay, 66 bacteriocins were screened, and 13 bacteriocins (PARAGEN collection, *n* = 12), including NAI-107, showed anti-gonococcal activity against the WHO-P strain. The sequences and the activity of the bacteriocins are provided in Table 1.

Four bacteriocins, GarKS (ABC), lacticin Q, lacticin Z, and NAI-107, showed higher activity against WHO-P, and their MICs were determined for 19 *Neisseria* isolates. The MIC of the four bacteriocins against these 19 isolates is provided in Table 2. NAI-107 showed an extended antimicrobial spectrum and was highly active against all *N. gonorrhoeae* isolates. Against all 14 tested *N. gonorrhoeae* isolates, the MICs ranged from 0.25 to 2 $\mu\text{g}/\text{mL}$, with no correlation with the isolate's ceftriaxone or azithromycin susceptibility profiles. The MIC of *N. meningitidis* was 4 $\mu\text{g}/\text{mL}$, and the MIC range of other *Neisseria* spp. was from 1 to >4 $\mu\text{g}/\text{mL}$ (Table 2). In contrast, the other bacteriocins, GarKS (ABC) (MIC range 4 to >16 $\mu\text{g}/\text{mL}$), lacticin Q (MIC range 16 to >16 $\mu\text{g}/\text{mL}$), and lacticin Z (MIC range 8 to >16 $\mu\text{g}/\text{mL}$), were substantially less active than NAI-107 against *Neisseria* species. GarKS (ABC), lacticin Q, and lacticin Z showed some activity against *N. gonorrhoeae* isolates but were inactive against *N. gonorrhoeae* WHO-N, *N. meningitidis*, and *Neisseria* commensals at the highest concentration tested (16 $\mu\text{g}/\text{mL}$) (Table 2).

In vivo toxicity of bacteriocins in *G. mellonella*

GarKS (ABC), lacticin Z, and NAI-107, which were active against the *N. gonorrhoeae* WHO-P isolate, were chosen for the *in vivo* experiments. GarKS (ABC), lacticin Z, and NAI-107 administered at doses up to 64 and 16 $\mu\text{g}/\text{mL}$, respectively, did not result in the death of the larvae (Fig. 2; Fig. S1a and b).

NAI-107 can protect *G. mellonella* larvae from infection with WHO-P *N. gonorrhoeae*

The *in vivo* efficacy of GarKS (ABC), lacticin Z, and NAI-107 was determined against *N. gonorrhoeae* WHO-P in comparison to ceftriaxone. Despite displaying *in vitro* activity against *N. gonorrhoeae*, the two bacteriocins, GarKS (ABC) and lacticin Z, did not demonstrate any detectable efficacy *in vivo* (Fig. S1a and b). NAI-107 was effective *in vivo* at all doses tested (*P* values 0.01 to <0.0001). A small dose-response effect may have been present, with mortality being lowest at the highest dose tested (16 $\mu\text{g}/\text{mL}$) and increasing stepwise at decreasing doses. At the two highest doses tested (8 and 16 $\mu\text{g}/\text{mL}$), the survival of *G. mellonella* was similar to that of the ceftriaxone group (Fig. 2).

Lack of *in vitro* resistance in *N. gonorrhoeae*

After subjecting *N. gonorrhoeae* WHO-P to four consecutive subcultures for 21 days in the presence of doubling concentrations of NAI-107, it resulted in a modest increase in the NAI-107 MIC, specifically a twofold increase (4 $\mu\text{g}/\text{mL}$).

TABLE 1 List of bacteriocins with anti-gonococcal activity detected in this study, their producer organisms, amino acid sequences, and *in vitro* activity against *N. gonorrhoeae* WHO-P^a

Bacteriocin	Abbreviation	Producer	Length (aa)	Amino acid sequence	Spot assay (zone of inhibition)
Garvicin KS - A	GarKS-A+B+C	<i>Lactococcus</i>	34	MGAIKAGAKIVGKGVGGASWLGWNVGEKIWK	+++
Garvicin KS - C		<i>garvieae</i>	32	MGAIKAGAKIVGKALTGGGVWLAELFGGK	
Garvicin KS - B			34	MGAIKAGAKIIGKLLGGAAGGATYGGKKIFG	
Lacticin Z	LcnZ	<i>L. lactis</i>	53	MAGFLKVQILAKYGSKAVQWAWANKGKILDWINAGQAIDWVVEKIKQILGIK	+++
Lacticin Q	LcnQ	<i>L. lactis</i>	53	MAGFLKVQLLAKYGSKAVQWAWANKGKILDWLNAGQAIDWVVKIKQILGIK	+++
Acidocin LF221B	Acd221B	<i>Lactobacillus</i>	48	NKWGNVAVIGATGATRGVSWCRGFGPWGMTACALGGAAGGYLYKSN	++
		<i>gasserii</i>			
Weissellicin M	WeisM	<i>Weissella</i>	43	MVSAAKVALKVGWGLVKYYTKVMQFIGEGWSVDQIADWLKRH	++
		<i>hellenica</i>			
Lacticin Z_C*	LcnZ_C*	<i>L. lactis</i>	48	MLAFLKLVAKLGPAAKWAWANKSRVLGWIRDMGMAIEWIINKINDIVN	+
Aureocin A53	AurA53	<i>S. aureus</i>	51	MSWLNFLKYIAKYGKKAWSAAWKYKGVLEWLVNVPPTLEWVWQKLLKIAGL	+
Enterocin 7A	Ent7A+B	<i>Enterococcus</i>	44	MGAIKLVAKFGWPIVKYKQIMQFIGEGWAINKIIDWIKKHI	+
Enterocin 7B		<i>faecium</i>	43	MGAIKLVAKFGWPFIKKFKYKQIMQFIGQGWTDQIEKWLRH	
Enterocin L50A	EntL50A+B	<i>E. faecium</i>	44	MGAIKLVAKFGWPIVKYKQIMQFIGEGWAINKIIEWIKKHI	+
Enterocin L50B			43	MGAIKLVTKFGWPLIKKFKYKQIMQFIGQGWTDQIEKWLRH	
Mutacin BHTB	MutBHTB	<i>Streptococcus</i>	44	MWGRILAFVAKYGTAKVQWAWKNKWFLLSLGEAVFDYIRSIWGG	+
		<i>rattus</i>			
Microbisporicin (prepropeptide)	NAI-107	<i>M. corallina</i>	57	MPADILETRTSETEDLLDLDSIGVEEITAGPAVTSWSLCTPGCTSPGGGSNCSFCC	+++

^aLow (+), moderate (++), and high (+++) anti-gonococcal activities of bacteriocins are shown. Bacteriocins with +++ activity were further chosen for MIC determination.

TABLE 2 Minimum inhibitory concentrations (MICs) of GarKS (ABC), lacticin Q, lacticin Z, and NAI-107 determined using the agar dilution method against 19 *Neisseria* spp., including *L. lactis* as a positive control^a

S. no.	Bacterial species	Strains	GarKS (ABC) (µg/mL)	Lacticin Q (µg/mL)	Lacticin Z (µg/mL)	NAI-107 (µg/mL)	Ceftriaxone (µg/mL)	Azithromycin (µg/mL)
1	<i>N. gonorrhoeae</i>	WHO G	8	16	8	1	0.008	0.25
2		WHO K	8	16	8	<0.25	0.064	0.25
3		WHO M	8	16	8	0.5	0.016	0.25
4		WHO L	16	16	16	1	0.25	0.5
5		WHO N	>16	>16	>16	2	0.004	0.25
6		WHO O	8	16	8	2	0.032	0.25
7		WHO P	8	16	8	1	0.004	4
8		WHO U	4	16	8	0.5	0.002	4
9		WHO V	16	16	8	2	0.064	>256
10		WHO W	8	16	8	1	0.064	0.5
11		WHO F	8	16	8	2	<0.002	0.125
12		WHO X	8	16	8	1	2	0.5
13		WHO Y	>16	>16	8	0.5	1	1
14		WHO Z	4	16	8	1	0.5	1
15	<i>N. meningitidis</i>	ITM-3354	>16	>16	>16	4	nd	nd
16	<i>Neisseria commensals</i>	<i>N. lactamica</i>	>16	16	16	1	nd	nd
17		<i>N. mucosa</i>	>16	>16	16	>4	nd	nd
18		<i>N. subflava</i>	>16	>16	>16	4	nd	nd
19		<i>N. cinerea</i>	>16	>16	16	2	nd	nd
20		<i>L. lactis</i>	<2	16	4	<0.25	nd	nd

^aCeftriaxone and azithromycin MICs have been adapted from reference (50). nd, not determined. For NAI-107 vs ceftriaxone, Pearson's correlation (r) = -0.207, P value = 0.477, and for NAI-107 vs azithromycin, r = 0.396, P value = 0.159.




FIG 2 *In vivo* efficacy (survival) of NAI-107 and ceftriaxone (20 mg/kg) against *N. gonorrhoeae*, the WHO-P reference strain in *G. mellonella* larvae. The test groups were injected with 2.7×10^7 CFU/mL of *N. gonorrhoeae*, the WHO-P strain in PBS, followed by NAI-107 (doses 4, 8, and 16 µg/mL) or ceftriaxone (20 mg/kg). The negative control group was injected with 30 µL of PBS, and the positive control group was injected with 2.7×10^7 CFU/mL of *N. gonorrhoeae* in PBS. Both the test and control groups consisted of 20 larvae and were incubated for 120 hours at 37°C. Error bars represent the standard errors. Asterisks represent the significance levels based on the *P* values comparing the survival curves between the PBS-positive controls and each treatment arm (Mantel-Cox test). A single asterisk (*) denotes a *P* value between 0.01 and 0.09. Two (**), three (***), and four (****) asterisks represent a *P* value in the range of 0.001–0.009, 0.0001–0.0009, and <0.0001, respectively.

DISCUSSION

Previously, microbisporicin (NAI-107) was reported to have *in vitro* efficacy against *N. gonorrhoeae* (33). Using a spot-on-lawn assay, we screened 65 bacteriocins from the PARAGEN collection along with NAI-107 against WHO-P *N. gonorrhoeae* (33, 51). Out of the 65 PARAGEN bacteriocins, a zone of inhibition was observed for 12 bacteriocins, and 3 bacteriocins showed the highest *in vitro* activity (Table 2). The *N. gonorrhoeae* MIC values of three PARAGEN bacteriocins, GarKS (ABC) (MIC range 4 to >16 µg/mL), lacticin Q (MIC range 16 to >16 µg/mL), and lacticin Z (MIC range 8 to >16 µg/mL), were higher than those for NAI-107 (MIC range <0.25 to 2 µg/mL). This MIC range was similar to that reported by the study of Brunati et al. (33), where the MIC range of *N. gonorrhoeae* (*n* = 18) isolates with intermediate or high resistance to penicillin had MICs that ranged from 0.015 to 2 µg/mL. Interestingly, there was no apparent correlation between the MIC of NAI-107 and *N. gonorrhoeae*'s ceftriaxone and azithromycin susceptibility profiles. In particular, the isolates with high ceftriaxone MICs had low NAI-107 MICs. This, in

conjunction with its similar half-life to ceftriaxone, makes it an attractive option for combination therapy to prevent the further emergence of ceftriaxone resistance (33). Our *in vivo* tests in *G. mellonella* confirmed the therapeutic efficacy and lack of toxicity of NAI-107. Finally, the *in vitro* passage experiments showed only a modest increase in the NAI-107 MIC; specifically, a twofold increase in MICs was observed. The same was observed in Gram-positive organisms, such as *S. aureus*, and interestingly, no spontaneous resistant mutants were observed (33, 54)

In contrast to NAI-107, the two PARAGEN bacteriocins [GarKS (ABC) and lacticin Z] did not demonstrate *in vivo* efficacy against *N. gonorrhoeae*; however, they showed no *in vivo* toxicity. The observed disparity between the *in vitro* and *in vivo* activities of the PARAGEN bacteriocins suggests the presence of additional factors influencing their efficacy *in vivo*. Several possibilities warrant consideration. Little is known about the pharmacodynamics and pharmacokinetics of these bacteriocins in the *G. mellonella* infection model (55–57). It is possible, for example, that NAI-107 is the only bacteriocin assessed that is not metabolized by the host. Various modes of action have been postulated for leaderless bacteriocins. Generally, leaderless bacteriocins have been shown not to involve a receptor/docking molecule to exhibit their antimicrobial action (46).

For instance, lacticin Q forms a huge toroidal pore (HTP) in the bacterial cell membrane, is translocated beneath the cell membrane, does not require a docking molecule, and is thus highly dependent on the physiological features of the cell membrane. This is thought to partly explain its limited spectrum of antibacterial activity and selective antimicrobial action (58, 59). The leaderless aureocin A53 produced by *S. aureus* A53 shows a stronger interaction with neutral membranes than negatively charged lipids and permeates the bacterial membranes without forming pores (60). In another instance, the leaderless bacteriocin LsbB, isolated from *L. lactis* subsp. *lactis* BGMN1–5, requires a zinc-dependent membrane metalloproteinase, YvjB, as its receptor molecule, which is contrary to the general understanding that leaderless bacteriocins do not require a receptor molecule for their mode of action (46, 61). The lantibiotic NAI-107, unlike nisin, does not form stable pores but causes depolarization of the membrane, resulting in bacterial cell death (28). It is thus plausible that the absence of a signal peptide and, in general, various modes of action of the leaderless peptides affects their processing, localization, or recognition by immune cells, leading to reduced efficacy *in vivo* (46). Further research is warranted to elucidate the underlying mechanisms responsible for the reduced *in vivo* activity of leaderless peptides, such as PARAGEN bacteriocins. Investigating these peptides' stability, secretion pathways, and host interactions could provide valuable insights into their efficacy and pave the way for their optimization as therapeutic agents.

The contrasting results observed for NAI-107 and the PARAGEN bacteriocins raise other interesting questions. While *in vitro* studies provide valuable initial insights, they may not fully reflect the complexity of the *in vivo* environment.

The study's caveats include a lack of testing in a mammalian model of *N. gonorrhoeae*. Notably, NAI-107 has been shown to be effective against methicillin-resistant *S. aureus* in a rat model (62). While no evidence of toxicity was detected in this study, further studies are required to assess toxicity in other animal models before NAI-107 can be tested in humans. Further testing should assess if there is evidence of synergy or antagonism between NAI-107 and ceftriaxone and other potential combination therapies.

Despite the above shortcomings, the results of the current work indicate that NAI-107 represents a promising option for addressing the severe threat of antibiotic resistance in *N. gonorrhoeae* and possibly in *N. meningitidis*.

ACKNOWLEDGMENTS

Conceptualization: S.S.M.-B. and C.K.; Methodology: N.H., Z.G., S.A., S.S.M.-B. and C.K.; Formal analysis: N.H., S.S.M.-B. and C.K.; Investigation: N.H., S.S.M.-B. and C.K.; Data curation: N.G., S.S.M.-B. and C.K.; writing—original draft preparation: S.S.M.-B. and C.K.;

writing—review and editing: Z.G, A.M, S.S.M.-B., and C.K. All authors have read and agreed to the published version of the manuscript.

AUTHOR AFFILIATIONS

¹Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium

²Clinical Reference Laboratory, Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium

³Syngulon, Seraing, Belgium

⁴Department of Medicine, University of Cape Town, Cape Town, South Africa

AUTHOR ORCIDs

Irith De Baetselier  <http://orcid.org/0000-0002-1804-252X>

Sheeba Santhini Manoharan-Basil  <http://orcid.org/0000-0001-8421-5137>

AUTHOR CONTRIBUTIONS

Nele Hofkens, Data curation, Formal analysis, Methodology | Zina Gestels, Methodology, Writing – review and editing | Said Abdellati, Methodology, Writing – review and editing | Irith De Baetselier, Writing – review and editing | Philippe Gabant, Writing – review and editing | Anandi Martin, Writing – review and editing | Christopher Kenyon, Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing.

ADDITIONAL FILES

The following material is available [online](#).

Supplemental Material

Supplemental Figure S1 (Spectrum02825-23-s0001.docx). Supplemental Figure S1a and b, showing two Kaplan-Meier plots.

REFERENCES

- O'Neill J. 2016. *Tackling drug-resistant infections globally: final report and recommendations*. Available from: <https://doi.org/https://doi.org/APO-63983>
- Miethke M, Pieroni M, Weber T, Brönstrup M, Hammann P, Halby L, Arimondo PB, Glaser P, Aigle B, Bode HB, Moreira R, Li Y, Luzhetskyy A, Medema MH, Pernodet J-L, Stadler M, Tormo JR, Genilloud O, Truman AW, Weissman KJ, Takano E, Sabatini S, Stegmann E, Brötz-Oesterheld H, Wohlleben W, Seemann M, Empting M, Hirsch AKH, Loretz B, Lehr C-M, Titz A, Herrmann J, Jaeger T, Alt S, Hesterkamp T, Winterhalter M, Schiefer A, Pfarr K, Hoerauf A, Graz H, Graz M, Lindvall M, Ramurthy S, Karlén A, van Dongen M, Petkovic H, Keller A, Peyrane F, Donadio S, Fraise L, Piddock LJV, Gilbert IH, Moser HE, Müller R. 2021. Towards the sustainable discovery and development of new antibiotics. *Nat Rev Chem* 5:726–749. <https://doi.org/10.1038/s41570-021-00313-1>
- AMR Industry alliance. 2021. 2021 progress report (AMR industry alliance, 2021)
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. 2022. *Lancet*:629–655.
- Fischbach MA, Walsh CT. 2009. Antibiotics for emerging pathogens. *Science* 325:1089–1093. <https://doi.org/10.1126/science.1176667>
- Newman DJ, Cragg GM. 2007. Natural products as sources of new drugs over the last 25 years. *J Nat Prod* 70:461–477. <https://doi.org/10.1021/np068054v>
- WHO. 2021. Global progress report on HIV, viral hepatitis and sexually transmitted infections
- Quillin SJ, Seifert HS. 2018. *Neisseria Gonorrhoeae* host adaptation and pathogenesis. *Nat Rev Microbiol* 16:226–240. <https://doi.org/10.1038/nrmicro.2017.169>
- Berger RE, Alexander ER, Harnisch JP, Paulsen CA, Monda GD, Ansell J, Holmes KK. 1979. Etiology, manifestations and therapy of acute epididymitis: prospective study of 50 cases. *J Urol* 121:750–754. [https://doi.org/10.1016/s0022-5347\(17\)56978-5](https://doi.org/10.1016/s0022-5347(17)56978-5)
- Reekie J, Donovan B, Guy R, Hocking JS, Kaldor JM, Mak D, Preen D, Ward J, Liu B, Chlamydia and Reproductive Health Outcome Investigators. 2019. Risk of ectopic pregnancy and tubal infertility following gonorrhoea and chlamydia infections. *Clin Infect Dis* 69:1621–1623. <https://doi.org/10.1093/cid/ciz145>
- Riou J, Althaus CL, Allen H, Cole MJ, Grad YH, Heijne JCM, Unemo M, Low N. 2023. Projecting the development of antimicrobial resistance in *neisseria gonorrhoeae* from antimicrobial surveillance data: a mathematical modelling study. *BMC Infect Dis* 23:252. <https://doi.org/10.1186/s12879-023-08200-4>
- Hassan M, Kjos M, Nes IF, Diep DB, Lotfipour F. 2012. Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance. *J Appl Microbiol* 113:723–736. <https://doi.org/10.1111/j.1365-2672.2012.05338.x>
- Ghodhbane H, Elaidi S, Sabatier J-M, Achour S, Benhmdia J, Regaya I. 2015. Bacteriocins active against multi-resistant gram negative bacteria implicated in nosocomial infections. *Infect Disord Drug Targets* 15:2–12. <https://doi.org/10.2174/1871526514666140522113337>

14. Marshall SH, Arenas G. 2003. Antimicrobial peptides: a natural alternative to chemical antibiotics and a potential for applied biotechnology. *J. Biotechnol* 6:271–284. <https://doi.org/10.2225/vol6-issue3-fulltext-1>
15. Cotter PD, Hill C, Ross RP. 2005. Bacteriocins: developing innate immunity for food. *Nat Rev Microbiol* 3:777–788. <https://doi.org/10.1038/nrmicro1273>
16. Entian KD, Klein C. 1993. Lantibiotics, a class of ribosomally synthesized peptide antibiotics. *Naturwissenschaften* 80:454–460. <https://doi.org/10.1007/BF01136035>
17. Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS, Bulaj G, Camarero JA, Campopiano DJ, Challis GL, Clardy J, Cotter PD, Craik DJ, Dawson M, Dittmann E, Donadio S, Dorrestein PC, Entian K-D, Fischbach MA, Garavelli JS, Göransson U, Gruber CW, Haft DH, Hemscheidt TK, Hertweck C, Hill C, Horswill AR, Jaspars M, Kelly WL, Klinman JP, Kuipers OP, Link AJ, Liu W, Marahiel MA, Mitchell DA, Moll GN, Moore BS, Müller R, Nair SK, Nes IF, Norris GE, Olivera BM, Onaka H, Patchett ML, Piel J, Reaney MJT, Rebuffat S, Ross RP, Sahl H-G, Schmidt EW, Selsted ME, Severinov K, Shen B, Sivonen K, Smith L, Stein T, Süßmuth RD, Tagg JR, Tang G-L, Truman AW, Vederas JC, Walsh CT, Walton JD, Wenzel SC, Willey JM, van der Donk WA. 2013. Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. *Nat. Prod. Rep* 30:108–160. <https://doi.org/10.1039/C2NP20085F>
18. McAuliffe O, Ross RP, Hill C. 2001. Lantibiotics: structure, biosynthesis and mode of action. *FEMS Microbiol Rev* 25:285–308. <https://doi.org/10.1111/j.1574-6976.2001.tb00579.x>
19. Guder A, Wiedemann I, Sahl HG. 2000. Posttranslationally modified bacteriocins—the Lantibiotics. *Biopolymers* 55:62–73. [https://doi.org/10.1002/1097-0282\(2000\)55:1<62::AID-BIP60>3.0.CO;2-Y](https://doi.org/10.1002/1097-0282(2000)55:1<62::AID-BIP60>3.0.CO;2-Y)
20. van Kraaij C, de Vos WM, Siezen RJ, Kuipers OP. 1999. Lantibiotics: biosynthesis, mode of action and applications. *Nat Prod Rep* 16:575–587. <https://doi.org/10.1039/a804531c>
21. Asaduzzaman SM, Sonomoto K. 2009. Lantibiotics: diverse activities and unique modes of action. *J Biosci Bioeng* 107:475–487. <https://doi.org/10.1016/j.jbiosc.2009.01.003>
22. Repka LM, Chekan JR, Nair SK, van der Donk WA. 2017. Mechanistic understanding of lanthipeptide biosynthetic enzymes. *Chem Rev* 117:5457–5520. <https://doi.org/10.1021/acs.chemrev.6b00591>
23. Foulston LC, Bibb MJ. 2010. Microbisporicin gene cluster reveals unusual features of lantibiotic biosynthesis in Actinomycetes. *Proc Natl Acad Sci U S A* 107:13461–13466. <https://doi.org/10.1073/pnas.1008285107>
24. Castiglione F, Lazzarini A, Carrano L, Corti E, Ciciliato I, Gastaldo L, Candiani P, Losi D, Marinelli F, Selva E, Parenti F. 2008. Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. *Chem Biol* 15:22–31. <https://doi.org/10.1016/j.chembiol.2007.11.009>
25. Sosio M, Gallo G, Pozzi R, Serina S, Monciardini P, Bera A, Stegmann E, Weber T. 2014. Draft genome sequence of the microbispora SP. In *Strain ATCC-PTA-5024*, producing the Lantibiotic NAI-107. <https://doi.org/10.1128/genomeA.01198-13>
26. Maffioli SI, Iorio M, Sosio M, Monciardini P, Gaspari E, Donadio S. 2014. Characterization of the congeners in the lantibiotic NAI-107 complex. *J Nat Prod* 77:79–84. <https://doi.org/10.1021/np400702t>
27. Foulston L, Bibb M. 2011. Feed-forward regulation of microbisporicin biosynthesis in *microbispora corallina*. *J Bacteriol* 193:3064–3071. <https://doi.org/10.1128/JB.00250-11>
28. Münch D, Müller A, Schneider T, Kohl B, Wenzel M, Bandow JE, Maffioli S, Sosio M, Donadio S, Wimmer R, Sahl H-G. 2014. The lantibiotic NAI-107 binds to bactoprenol-bound cell wall precursors and impairs membrane functions. *J Biol Chem* 289:12063–12076. <https://doi.org/10.1074/jbc.M113.537449>
29. Matsusaki H, Endo N, Sonomoto K, Ishizaki A. 1996. Lantibiotic nisin Z fermentative production by *Lactococcus lactis* iO-1: relationship between production of the lantibiotic and lactate and cell growth. *Appl Microbiol Biotechnol* 45:36–40. <https://doi.org/10.1007/s002530050645>
30. Fujita K, Ichimasa S, Zendo T, Koga S, Yoneyama F, Nakayama J, Sonomoto K. 2007. Structural analysis and characterization of lactacin Q, a novel bacteriocin belonging to a new family of unmodified bacteriocins of gram-positive bacteria. *Appl Environ Microbiol* 73:2871–2877. <https://doi.org/10.1128/AEM.02286-06>
31. Iwatani S, Zendo T, Yoneyama F, Nakayama J, Sonomoto K. 2007. Characterization and structure analysis of a novel bacteriocin, lactacin Z, produced by *Lactococcus lactis* QU 14. *Biosci Biotechnol Biochem* 71:1984–1992. <https://doi.org/10.1271/bbb.70169>
32. Ovchinnikov KV, Chi H, Mehmeti I, Holo H, Nes IF, Diep DB. 2016. Novel group of leaderless multipetide bacteriocins from gram-positive bacteria. *Appl Environ Microbiol* 82:5216–5224. <https://doi.org/10.1128/AEM.01094-16>
33. Brunati C, Thomsen TT, Gaspari E, Maffioli S, Sosio M, Jabes D, Løbner-Olesen A, Donadio S. 2018. Expanding the potential of NAI-107 for treating serious ESKAPE pathogens: synergistic combinations against gram-negatives and bactericidal activity against non-dividing cells. *J Antimicrob Chemother* 73:414–424. <https://doi.org/10.1093/jac/dkx395>
34. Chi H, Holo H. 2018. Synergistic antimicrobial activity between the broad spectrum bacteriocin garvicin KS and nisin, farnesol and polymyxin B against gram-positive and gram-negative bacteria. *Curr Microbiol* 75:272–277. <https://doi.org/10.1007/s00284-017-1375-y>
35. Maffioli SI, Cruz JCS, Monciardini P, Sosio M, Donadio S. 2016. Advancing cell wall inhibitors towards clinical applications. *J Ind Microbiol Biotechnol* 43:177–184. <https://doi.org/10.1007/s10295-015-1703-9>
36. Hoffmann JA. 1995. Innate immunity of insects. *Curr Opin Immunol* 7:4–10. [https://doi.org/10.1016/0952-7915\(95\)80022-0](https://doi.org/10.1016/0952-7915(95)80022-0)
37. Jander G, Rahme LG, Ausubel FM. 2000. Positive correlation between virulence of *Pseudomonas aeruginosa* mutants in mice and insects. *J Bacteriol* 182:3843–3845. <https://doi.org/10.1128/JB.182.13.3843-3845.2000>
38. Fedhila S, Daou N, Lereclus D, Nielsen-LeRoux C. 2006. Identification of bacillus cereus Internalin and other candidate virulence genes specifically induced during oral infection in insects. *Mol Microbiol* 62:339–355. <https://doi.org/10.1111/j.1365-2958.2006.05362.x>
39. Evans BA, Rozen DE. 2012. A streptococcus pneumoniae infection model in larvae of the wax moth *Galleria mellonella*. *Eur J Clin Microbiol Infect Dis* 31:2653–2660. <https://doi.org/10.1007/s10096-012-1609-7>
40. Desbois AP, Coote PJ. 2011. Wax moth larva (*Galleria mellonella*): an *in vivo* model for assessing the efficacy of antistaphylococcal agents. *J Antimicrob Chemother* 66:1785–1790. <https://doi.org/10.1093/jac/dkr198>
41. Gibreel TM, Upton M. 2013. Synthetic epidermicin NI01 can protect *Galleria mellonella* larvae from infection with *Staphylococcus aureus*. *J Antimicrob Chemother* 68:2269–2273. <https://doi.org/10.1093/jac/dkt195>
42. Djokaite A, Humbert MV, Borkowski E, La Ragione RM, Christodoulides M. 2021. Establishing an invertebrate *Galleria mellonella* greater wax moth larval model of *Neisseria gonorrhoeae* infection. *Virulence* 12:1900–1920. <https://doi.org/10.1080/21505594.2021.1950269>
43. Djokaite A, Humbert V-M, Christodoulides M. 2020. *Galleria mellonella* – a novel infection model for the study of *Neisseria gonorrhoeae* virulence and pathogenicity. *Access Microbiology* 2. <https://doi.org/10.1099/acmi.ac2020.po1042>
44. Cui Y, Zhang C, Wang Y, Shi J, Zhang L, Ding Z, Qu X, Cui H. 2012. Class IIa bacteriocins: diversity and new developments. *Int J Mol Sci* 13:16668–16707. <https://doi.org/10.3390/ijms131216668>
45. Gabrielsen C, Brede DA, Nes IF, Diep DB. 2014. Circular bacteriocins: biosynthesis and mode of action. *Appl Environ Microbiol* 80:6854–6862. <https://doi.org/10.1128/AEM.02284-14>
46. Perez RH, Zendo T, Sonomoto K. 2018. Circular and leaderless bacteriocins: biosynthesis, mode of action, applications, and prospects. *Front Microbiol* 9:2085. <https://doi.org/10.3389/fmicb.2018.02085>
47. Newstead LL, Varjonen K, Nuttall T, Paterson GK. 2020. Staphylococcal-produced bacteriocins and antimicrobial peptides: their potential as alternative treatments for *Staphylococcus aureus* infections. *Antibiotics (Basel)* 9:40. <https://doi.org/10.3390/antibiotics9020040>
48. Benítez-Chao DF, León-Buitimea A, Lerma-Escalera JA, Morones-Ramírez JR. 2021. Bacteriocins: an overview of antimicrobial, toxicity, and biosafety assessment by *in vivo* models. *Front. Microbiol* 12:630695. <https://doi.org/10.3389/fmicb.2021.630695>
49. Tsoumanis A, Van Dijck C, Hens N, Kenyon C. 2023. Rethinking screening intensity in terms of reducing prevalence or increasing selection pressure for the emergence of resistant gonorrhoea: a modeling study of men who have sex with men in Belgium. *Open Forum Infect Dis* 10:fad165. <https://doi.org/10.1093/ofid/ofad165>

50. Unemo M, Golparian D, Sánchez-Busó L, Grad Y, Jacobsson S, Ohnishi M, Lahra MM, Limnios A, Sikora AE, Wi T, Harris SR. 2016. The novel 2016 WHO neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. *J Antimicrob Chemother* 71:3096–3108. <https://doi.org/10.1093/jac/dkw288>
51. Gabant P, Borrero J. 2019. PARAGEN 1.0: a standardized synthetic gene library for fast cell-free bacteriocin synthesis. *Front Bioeng Biotechnol* 7:213. <https://doi.org/10.3389/fbioe.2019.00213>
52. CLSI. 2023. Performance standards for antimicrobial disk susceptibility tests. In CLSI, performance standards for antimicrobial disk susceptibility tests, 33rd ed
53. Jaumaux F, Petit K, Martin A, Rodriguez-Villalobos H, Vermeersch M, Perez-Morga D, Gabant P. 2023. Selective bacteriocins: a promising treatment for staphylococcus aureus skin infections reveals insights into resistant mutants. *Antibiotics* 12:947. <https://doi.org/10.3390/antibiotics12060947>
54. Foulston L. 2010. Cloning and analysis of the microbisporicin lantibiotic gene cluster from *Microbispora corallina*, Doctoral thesis, University of East Anglia
55. Tsai C-Y, Loh JMS, Proft T. 2016. *Galleria mellonella* infection models for the study of bacterial diseases and for antimicrobial drug testing. *Virulence* 7:214–229. <https://doi.org/10.1080/21505594.2015.1135289>
56. Pereira MF, Rossi CC, da Silva GC, Rosa JN, Bazzolli DMS. 2020. *Galleria mellonella* as an infection model: An in-depth look at why it works and practical considerations for successful application. *Pathog Dis* 78:ftaa056. <https://doi.org/10.1093/femspd/ftaa056>
57. Ménard G, Rouillon A, Cattoir V, Donnio P-Y. 2021. *Galleria mellonella* as a suitable model of bacterial infection: past, present and future. *Front Cell Infect Microbiol* 11:782733. <https://doi.org/10.3389/fcimb.2021.782733>
58. Yoneyama F, Ohno K, Imura Y, Li M, Zendo T, Nakayama J, Matsuzaki K, Sonomoto K. 2011. Lactacin Q-mediated selective toxicity depending on physicochemical features of membrane components. *Antimicrob Agents Chemother* 55:2446–2450. <https://doi.org/10.1128/AAC.00808-10>
59. Yoneyama F, Imura Y, Ohno K, Zendo T, Nakayama J, Matsuzaki K, Sonomoto K. 2009. Peptide-lipid huge toroidal pore, a new antimicrobial mechanism mediated by a lactococcal bacteriocin, lactacin Q. *Antimicrob Agents Chemother* 53:3211–3217. <https://doi.org/10.1128/AAC.00209-09>
60. Netz DJA, Bastos M do C de F, Sahl HG. 2002. Mode of action of the antimicrobial peptide aureocin A53 from staphylococcus aureus. *Appl Environ Microbiol* 68:5274–5280. <https://doi.org/10.1128/AEM.68.11.5274-5280.2002>
61. Uzelac G, Kojic M, Lozo J, Aleksandrak-Piekarczyk T, Gabrielsen C, Kristensen T, Nes IF, Diep DB, Topisirovic L. 2013. A Zn-dependent metallopeptidase is responsible for sensitivity to lsbb, a class II leaderless bacteriocin of lactococcus lactis subsp. lactis bgmn1-5. *J Bacteriol* 195:5614–5621. <https://doi.org/10.1128/JB.00859-13>
62. Jabés D, Brunati C, Candiani G, Riva S, Romanó G, Donadio S. 2011. Efficacy of the new Lantibiotic NAI-107 in experimental infections induced by multidrug-resistant gram-positive pathogens. *Antimicrob Agents Chemother* 55:1671–1676. <https://doi.org/10.1128/AAC.01288-10>